篇名

從胰島素漲價論美國醫療保險制度   免費試閱

並列篇名

Insulin’s Steep Price Leads to the Discussion of U.S. Medical Insurance Systems

作者
中文摘要

自2012年以來,美國境內的胰島素價格成長了一倍多。患者保護與平價醫療法案下的自付額保險制度,卻可能造成患者獲得救命激素的困境,肇因於保險給付制度無法幫助真正需要的人,如無業族群、青少年或老年人,因根據現行法律,這些人永遠無法獲得醫療補助或醫療保險的資格。即使有醫療保險,也必須超過自付額,保險公司才會幫保戶負擔,如果連自付額都繳不起,根本無法享有福利。也有些人指責中間商(如藥房,如Express Scripts和CVS Health)與製藥公司商議降低價格而不向客戶節省成本。也有人指出三大主要胰島素製造商:法國的賽諾菲、丹麥的諾和諾德和美國禮來製藥公司,應該為哄抬價格承擔大部分責任。這三家製藥商受到麻薩諸塞州的糖尿病患者起訴,委任律師聲稱價格上漲是以犧牲患者的健康為代價。

英文摘要

The price of insulin in the U.S. has increased more than double since 2012. That’s put the lifesaving hormone out of reach for some people with diabetes. The deductible of the Patient Protection and Affordable Care Act (PPACA) has gotten patient out-of-pocket before his/her insurance is even going to kick in. People get a different response for why insulin prices have risen so high. Some blame middlemen — such as pharmacy benefit managers — for negotiating lower prices with pharmaceutical companies without passing savings on to customers. Much of the blame should fall on the three main manufacturers of insulin today: Sanofi of France, Novo Nordisk of Denmark and Eli Lilly in the U.S. The three companies are being sued in U.S. Federal Court by diabetic patients in Massachusetts who allege the prices are rising at the expense of patients’ health.

起訖頁

168-176

出版單位
DOI

10.3966/241553062019100036012  複製DOI  DOI查詢

QRCode

下一篇
數位整合服務
產品服務
讀者服務專線:+886-2-23756688   傳真:+886-2-23318496   地址:臺北市館前路28號7樓

Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄
TOP